Compare DexCom, Inc. (DXCM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? DexCom, Inc. trades at $83.72 (market cap $31.86B), while Regeneron Pharmaceuticals Inc trades at $742.38 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.4× DexCom, Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DXCM | REGN | |
|---|---|---|
Market Cap | $31.86B | $76.14B |
Volume | 3,607,070 | 500,239 |
Sector | Health | Health |
52-Week High | $92.34 | $852.03 |
52-Week Low | $54.84 | $557.73 |
Typical Hold Time | 62 Days | 107 Days |
Enterprise Value | $31.32B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
